Literature DB >> 12714880

Prospective evaluation of efficacy and toxicity of 5-fu and folinic acid (Mayo Clinic regimen) in patients with advanced cancer of the gallbladder.

Imtiaz A Malik1, Zeba Aziz.   

Abstract

We evaluated the efficacy and toxicity of 5-fluorouracil (5-FU) and folinic acid (Mayo Clinic regimen) in previously untreated patients with advanced gallbladder cancer. Thirty patients with histologically confirmed adenocarcinoma of gallbladder were enrolled on this trial. All were symptomatic and had stage IV disease. Patients received 5-FU 425 mg/m2 daily for 5 consecutive days preceded by folinic acid 20 mg/m2/d. Treatment cycles were repeated every 28 days. Only two patients (7%) achieved an objective response to therapy. Another 10 (33%) had stable disease. Median time to progression was 4.7 months, and median overall survival was 14.8 months. Toxicity was moderate, and one treatment-related death occurred. In conclusion, 5-FU and folinic acid (Mayo Clinic regimen) is ineffective in the management of patients with advanced gallbladder cancer, and further trials with this regimen are not recommended.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12714880     DOI: 10.1097/00000421-200304000-00004

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  7 in total

1.  Identification of active chemotherapy regimens in advanced biliary tract carcinoma: a review of chemotherapy trials in the past two decades.

Authors:  Susanna V Ulahannan; Osama E Rahma; Austin G Duffy; Oxana V Makarova-Rusher; Metin Kurtoglu; David J Liewehr; Seth M Steinberg; Tim F Greten
Journal:  Hepat Oncol       Date:  2015-01-01

Review 2.  Signaling pathways as therapeutic targets in biliary tract cancer.

Authors:  Jennifer Yang; Matthew R Farren; Daniel Ahn; Tanios Bekaii-Saab; Gregory B Lesinski
Journal:  Expert Opin Ther Targets       Date:  2017-03-17       Impact factor: 6.902

3.  Surgery and chemotherapy for intrahepatic cholangiocarcinoma.

Authors:  Zenichi Morise; Atsushi Sugioka; Takamasa Tokoro; Yoshinao Tanahashi; Yasuhiro Okabe; Tadashi Kagawa; Chinatsu Takeura
Journal:  World J Hepatol       Date:  2010-02-27

4.  Upregulation of topoisomerase IIalpha expression in advanced gallbladder carcinoma: a potential chemotherapeutic target.

Authors:  Mitsutsune Washiro; Masayuki Ohtsuka; Fumio Kimura; Hiroaki Shimizu; Hiroyuki Yoshidome; Takashi Sugimoto; Naohiko Seki; Masaru Miyazaki
Journal:  J Cancer Res Clin Oncol       Date:  2008-01-17       Impact factor: 4.553

5.  A phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-dose consecutive (Cisplatin) CDDP) in advanced biliary tract carcinoma.

Authors:  Kazuma Kobayashi; Akihito Tsuji; Sojiro Morita; Tadashi Horimi; Tetsuhiko Shirasaka; Takashi Kanematsu
Journal:  BMC Cancer       Date:  2006-05-06       Impact factor: 4.430

6.  The Efficacy of Different Chemotherapy Regimens for Advanced Biliary Tract Cancer: A Systematic Review and Network Meta-Analysis.

Authors:  Yan Li; Yaoyao Zhou; Yonglan Hong; Meizhi He; Shuyi Wei; Chen Yang; Dayong Zheng; Feiye Liu
Journal:  Front Oncol       Date:  2019-05-29       Impact factor: 6.244

7.  Guidelines for chemotherapy of biliary tract and ampullary carcinomas.

Authors:  Junji Furuse; Tadahiro Takada; Masaru Miyazaki; Shuichi Miyakawa; Kazuhiro Tsukada; Masato Nagino; Satoshi Kondo; Hiroya Saito; Toshio Tsuyuguchi; Koichi Hirata; Fumio Kimura; Hideyuki Yoshitomi; Satoshi Nozawa; Masahiro Yoshida; Keita Wada; Hodaka Amano; Fumihiko Miura
Journal:  J Hepatobiliary Pancreat Surg       Date:  2008-02-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.